Grifols, S.A. (GRFS) — closed signal from September 16, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 15, 2025.
Predicted vs. what happened
What happened
Reached 16% of the predicted growth at its peak, without hitting the target.
The thesis — published September 16, 2025
Grifols looks like a value idea that could bounce back after a sharp drop. The price seems unusually beaten down. The company plans to roughly double plasma capacity in Europe around 09-11, which could lift profits. Independent checks suggest the shares look cheap. Treat this as a 3-month rebound plan with clear exits because debt levels raise the risk, and only if execution stays on track.
Primary drivers
- Price looks unusually beaten down, which can set up a near-term rebound.
- Europe capacity plan around 09-11 aims to roughly double plasma output.
- Independent value checks and a noted Buy rating suggest the stock is cheap.
- Short-term trade idea with strict exit rules to control downside risk.
How it played out
GRFS: target was not reached
Lyra published GRFS at 9.95 on 2025-09-16 as a short-term rebound idea with 18% expected growth. The thesis pointed to a beaten-down price, a Europe plasma capacity plan around 09-11, independent value checks, a noted Buy rating, and strict exit rules because debt raised the risk.
Inside the window, GRFS peaked at 10.23 on 2025-10-02, a 2.9% gain. That stayed below the 11.74 target. It never got there. By 2025-12-15, the stock ended at 9.03. The thesis missed on the measured price outcome.
What happened during the window
On 2025-11-04, Grifols reported third-quarter revenue of 1,865 million euros, up 9.1%, and said nine-month revenue was 5,542 million euros. The article also said adjusted EBITDA through September was 1,358 million euros, up 11.2%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.